Related Experiment Video
Updated: Jun 16, 2026
Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
N-acetylcysteine alleviates experimental autoimmune prostatitis in rats by activating PI3K/Akt/CREB and Keap1/Nrf2
Changjing Wu1, Fudong Fu2, Yang Xiong1,3
1Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Background:
The pathogenesis of non-bacterial chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) remains incompletely understood. Aberrant autoimmune responses have emerged as a prominent hypothetical contributor to CP/CPPS development. N-acetylcysteine (NAC), a well-established antioxidant agent, has demonstrated therapeutic efficacy in multiple disease models. This study aimed to systematically investigate the protective effects of NAC in experimental autoimmune prostatitis (EAP) rat models, with parallel exploration of its molecular mechanisms.
Methods:
Prostate tissues from ten rats were prepared as antigen to the establish EAP rat model. Twenty-four rats were randomly assigned to three groups: control (CON), EAP, and EAP + NAC. After 4 weeks of NAC treatment, mechanical allodynia was assessed using von-Frey filaments. Western blot, enzyme linked immunosorbent assay and immunohistochemistry were used to measure molecular expression. Hematoxylin-eosin and immunofluorescence staining were used to visualize inflammatory infiltration.
Results:
Compared to the CON and EAP + NAC groups, the EAP group showed significantly increased mechanical allodynia, along with markedly higher levels of inflammatory markers and oxidative stress. Further mechanistic studies revealed that both the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/cAMP-response element binding protein (CREB) signaling axis and the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway were substantially more activated in the CON and EAP+NAC groups than in the untreated EAP rats.
Conclusions:
This study demonstrated that NAC could effectively ameliorate CP/CPPS by specifically activating the PI3K/Akt/CREB and Keap1/Nrf2 pathways.
Insights
N-acetylcysteine (NAC) effectively treats experimental autoimmune prostatitis in rats by reducing pain and inflammation. It works by activating specific molecular pathways, offering a potential therapeutic strategy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Area of Science:
- Urology
- Immunology
- Pharmacology
Background:
- Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) pathogenesis is unclear, with autoimmune responses a suspected cause.
- N-acetylcysteine (NAC), an antioxidant, shows promise in various disease models.
- This study investigates NAC's protective effects in experimental autoimmune prostatitis (EAP) and its mechanisms.
Purpose of the Study:
- To evaluate the therapeutic efficacy of N-acetylcysteine (NAC) in a rat model of experimental autoimmune prostatitis (EAP).
- To elucidate the molecular mechanisms underlying NAC's protective effects in EAP.
- To explore NAC as a potential treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Main Methods:
- Established an EAP rat model using prostate tissue antigen.
- Administered NAC to EAP rats for 4 weeks and assessed mechanical allodynia.
- Utilized Western blot, ELISA, and immunohistochemistry to analyze molecular markers and inflammatory infiltration.
Main Results:
- EAP rats exhibited significantly increased mechanical allodynia, inflammation, and oxidative stress compared to controls.
- NAC treatment significantly reduced mechanical allodynia and inflammatory markers in EAP rats.
- NAC administration activated the PI3K/Akt/CREB and Keap1/Nrf2/HO-1 pathways.
Conclusions:
- N-acetylcysteine (NAC) effectively ameliorates symptoms in experimental autoimmune prostatitis (EAP).
- NAC exerts its therapeutic effects by activating the PI3K/Akt/CREB and Keap1/Nrf2 pathways.
- NAC shows potential as a novel therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).